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Background. Dendritic cells regulate immune responses to microbial products and play a key role in ulcerative colitis (UC)
pathology. We determined the immunomodulatory effects of probiotic strain Lactobacillus casei Shirota (LcS) on human DC from
healthy controls and active UC patients.Methods. Human bloodDC from healthy controls (control-DC) andUC patients (UC-DC)
were conditioned with heat-killed LcS and used to stimulate allogeneic T cells in a 5-day mixed leucocyte reaction. Results. UC-DC
displayed a reduced stimulatory capacity for T cells (𝑃 < 0.05) and enhanced expression of skin-homing markers CLA and CCR4
on stimulated T cells (𝑃 < 0.05) that were negative for gut-homing marker 𝛽7. LcS treatment restored the stimulatory capacity
of UC-DC, reflecting that of control-DC. LcS treatment conditioned control-DC to induce CLA on T cells in conjunction with
𝛽7, generating a multihoming profile, but had no effects on UC-DC. Finally, LcS treatment enhanced DC ability to induce TGF𝛽
production byT cells in controls but notUCpatients.Conclusions.We demonstrate a systemic, dysregulatedDC function inUC that
may account for the propensity of UC patients to develop cutaneous manifestations. LcS has multifunctional immunoregulatory
activities depending on the inflammatory state; therapeutic effects reported in UC may be due to promotion of homeostasis.
1. Introduction
Interactions between the host and microbiota play a crucial
role in mucosal immune homeostasis [1]. Certain strains
of lactic-acid producting bacteria are classed as probiotics
because their consumption is associated with health benefits,
which are mediated via the gut. The current probiotic defi-
nition is “live microorganisms which when administered in
adequate amounts confer a healthy benefit on the host” [2].
Probiotic bacteria are most frequently of the Lactobacillus
or Bifidobacterium species, and usually species that can be
found in the normal commensal microbiota. Probiotics can
be effective in treating some patients with inflammatory
bowel disease (IBD) [3–7] but the details of which strains
confer benefit and their mechanisms of action are only slowly
being defined.
Ulcerative colitis (UC) and Crohn’s disease (CD), collec-
tively termed inflammatory bowel disease (IBD), result from
a dysregulated response of the mucosal immune system to
components of the luminal microbiota, and breakdown of
immune tolerance in individuals who are genetically predis-
posed to the disease These processes lead to “inappropriate”
activation ofmucosal T-cells and production of inflammatory
mediators [8–11].
2 Mediators of Inflammation
Dendritic cells (DC) recognize and respond to bac-
teria and bacterial products, and generate primary T-cell
responses. DC also determine whether T-cell responses
generated are immunogenic or tolerogenic [12–14]. In par-
ticular, intestinal DC maintain the delicate balance in the
gut between immunogenicity against invading pathogens and
tolerance of the commensal microbiota [15]; alterations in
intestinal DC have been found in IBD [15, 16]. The effects
of probiotic bacteria on DC, which are so pivotal in early
bacterial recognition, tolerance induction and shaping T-
cell responses, are likely to be central in immunomodulation
by these bacteria, and are likely to partially account for the
reported efficacy of probiotics in IBD [3–7].
IBD is associated with a variety of extra-intestinal mani-
festations (EIM),with up to a third of IBDpatients developing
cutaneous manifestations [17]. The causes of EIM are poorly
understood, but it has been suggested that compartmental-
isation of inflammatory processes to different organs (e.g.,
the intestines, skin or liver) may be linked to homing
and trafficking of immune cells [18]. Indeed, dysregulated
lymphocyte trafficking has been reported in bothUC andCD
[19–22].
Homing properties are imprinted on T-cells upon stim-
ulation by DC, to localise immune responses to specific
tissues [23–26]. Effector T-cells migrating to intestinal sites
express high levels of gut-homing molecule 𝛼
4
𝛽
7
[27], with
its ligandMAdCAM-1 being constitutively expressed by post-
capillary endothelial cells in the small intestine [28] and
colonic lamina propria [29]. Skin T-cells express E- and P-
selectin ligands including cutaneous lymphocyte-associated
antigen (CLA) [30], and CCR4 [31]. The occurrence of EIM
associated with IBD indicates a systemic disease, rather than
immune dysregulation confined to intestinal sites; however
it is currently unclear whether alterations in circulating DC
occur in IBD patients, including DC ability to imprint
specific homing properties on stimulated T-cells. Trafficking
of immune cells is an area yet to be investigated regarding
specific mechanisms of action of immunomodulation by
probiotics or dysregulated DC function in IBD.
The strain-specific nature of the immunomodulatory
effects of probiotics is well established; some Lactobacillus
strains induce production of regulatory cytokines, suppress
Th1 responses and are thought to be involved in oral
tolerance. In contrast, other strains induce production of
pro-inflammatory cytokines. However, human intervention
studies have shown a variety of beneficial immunomodu-
latory effects associated with consumption of the probiotic
bacterial strain Lactobacillus casei Shirota (LcS) specifically,
including significant improvement in UC disease activity
index (UCDAI) scores in patients with mild-moderate UC
administered LcS orally for 8 weeks, compared to pre-
treatment and also patients on conventional therapy. The
same study demonstrated LcS reduces production of IL-6
from peripheral blood mononuclear cells (PBMC) in vitro
[32]. Other studies demonstrate reduction of gingival inflam-
mation [33], and downregulation of allergic responses [34]
following consumption of LcS. To this end, we aimed to
determine whether systemic changes exist between healthy
controls and patients with active UC, regarding the ability of
circulating (blood-enriched) DC to generate effector T-cell
responses and imprint specific homing properties on T-cells
stimulated. We also aimed to study the immunomodulatory
effects of probiotic strain LcS on such DC.
2. Materials and Methods
2.1. Human Peripheral Blood. Human peripheral blood was
collected from healthy volunteers with no known autoim-
mune or inflammatory diseases, allergies or malignancies
(𝑛 = 8), or from patients with active UC following informed
consent (𝑛 = 6). Disease activity for UC was assessed using
the UC disease activity index (UCDAI); patients scoring
UCDAI 4–12, alongside diagnosis from clinical parameters,
radiographic studies, endoscopic and histological criteria,
were defined as active UC. Patients were treatment naı¨ve
or on minimal treatment: 5-aminosalicylic acid (5ASA)
and/or azathioprine (AZA). Peripheral blood mononuclear
cells (PBMC) were obtained by centrifugation over Ficoll-
Paque plus (Amersham Biosciences, Chalfont St. Giles, UK).
Human blood-enriched DC (low density cells or LDC) were
obtained followingNycoPrep centrifugation of overnight cul-
tured PBMC.These cells were 98–100%HLA-DR+, withmor-
phological characteristics of DC (both at optical microscopy
and electronmicroscopy), and are potent stimulators of na¨ıve
T-cells. Blood LDC have been characterised in detail in
previous studies from our laboratory [35, 36], and will be
referred to as blood DC in this study.
2.2. Conditioning of Human Blood DC by LcS. Stock culture
of LcS (Yakult Honsha Co. Ltd., Tokyo, Japan) were cultured
at 37∘C for 24 hours in MRS broth and grown on MRS
agar (Oxoid, Hampshire, UK) for 48 hours at 37∘C in an
anaerobic cabinet (MACS MG 1000; Don Whitley Scientific,
West Yorkshire, UK) with a gas mixture of 10% H
2
, 10%
CO
2
and 80% N
2
by volume. For liquid culture, one pure
colony was taken from anMRS nutrient agar plate and grown
overnight in 10mL of pre-reduced MRS broth (Oxoid) with
0.05% L-cysteine hydrochloride (Sigma, Dorset, UK) in a
shaking incubator at 37∘C; 0.5mL of the overnight culture
was inoculated into another 10mL MRS broth. The bacteria
were harvested in the exponential phase, resuspended in
phosphate-buffered saline (PBS; Oxoid), centrifuged twice
at 1960 g (Sanyo/MSE Micro Centaur, Haverhill, USA) for 5
minutes and resuspended at the required concentration in
RPMI 1640 containing 0.75mM L-glutamine. Bacteria were
then heat-killed with viability checks done to make sure no
bacteria survived, and varying concentrations (1× 105, 1× 106,
or 1 × 107) of heat-killed LcS were used to condition 2.5 × 105
blood DC in 1mL total volume of complete medium (Dutch
modification RPMI 1640 containing 2mM glutamine, 10%
fetal calf serum and 100U/mL penicillin/streptomycin) for
24 hours. Control conditions involved conditioning DC with
complete medium only for 24 hours. Following conditioning,
DC were washed, and used in a mixed-leucocyte reaction
(MLR) with allogeneic T-cells.
2.3. Enrichment of Blood T-Cells. PBMC were suspended in
MiniMACS buffer (PBS containing 0.5% BSA and 2mM
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EDTA) and T-cells were enriched by depletion of CD14+,
CD19+ and HLA-DR+ cells with immunomagnetic beads
(Miltenyi Biotech, Bisley, UK) following manufacturer’s
instructions.
2.4. T-Cell Proliferation Assay. Carboxyfluorescein diacetate
succinimidyl ester (CFSE, Invitrogen Ltd, UK) labelled
T-cells (4 × 105/well) were incubated for 5 days in U-
bottomed 96 well microtitre plates with enriched, previously
conditioned, allogeneic DC at 0%, 1%, 2%, or 3% in a mixed
leukocyte reaction (MLR). Cells were recovered and CFSElo
proliferating cells identified and quantified by flow cytometry.
2.5. Antibody Labelling. Monoclonal antibodies with the
following specificities and conjugations were used: CLA-
FITC (HECA-452), 𝛽7 integrin-PE (FIB504), IL-12 (p40/
p70)-PE (C11.5), IL-17A-PE (SCPL1362), CD3-PerCPCy5.5
(SK7), CD3-PeCy5 (UCHT1), IL-10-APC (JES3-19F1), IFN𝛾
(25723.11), CLA-biotin (HECA-452) and Strepavidin-APC
were purchased from BD Biosciences (Oxford, UK); CCR9
(either—FITC or—APC) (112509), CCR7-PE (150503),
CCR10-APC (314315), CCR4-APC (205410) and TGF𝛽
(IC388P) were purchased from R&D Systems (Abingdon,
UK). Appropriate isotype-matched control antibodies were
purchased from the same manufacturers. After the staining,
cells were fixed with 1% paraformaldehyde in 0.85% saline
and stored at 4∘C prior to acquisition on the flow cytometer,
within 48 hours.
2.6. Flow Cytometry and Data Analysis. Data were acquired
on a FACSCanto II cytometer (BD Biosciences) and analysed
using WinList 5.0 software (Verity, ME, US). Proportions of
positive cells were measured by subtracting the appropriate
isotype-matched control staining from test histogram using
superenhanced Dmax (SED) normalised subtraction.
2.7. Cytokine Analysis. The intracellular cytokine production
by stimulatedT-cells post-MLRwasmeasured using superen-
hanced Dmax (SED) normalised subtraction upon data analy-
sis following incubation +/− monensin, T-cell permeabilisa-
tion, antibody labelling and flow cytometry.
2.8. Statistical Analyses. Data are presented as mean and
standard errors. Two-way repeated measures ANOVA, and
two-tailed paired 𝑡-tests were applied as stated in the figure
legends. In the case of multiple comparisons, subsequent
ad-hoc Bonferroni correction was applied. 𝑃 < 0.05 was
considered significant.
3. Results
3.1. Characteristics of Human DC Function in UC
3.1.1. Reduced T-Cell Stimulatory Capacity of DC in UC.
We analysed DC stimulation of T-cells in a 5-day mixed
leucocyte reaction (MLR). T-cells from the same donor
(a separate, healthy control) were stimulated by DC from
healthy controls and UC patients, within the same experi-
ments. DC stimulated a strong, dose-dependent proliferative
response in both healthy controls and UC patients; dividing
T-cells were identified as CFSElo CD3+ lymphocytes, by flow
cytometry (Figure 1(a)).However,DC fromUCpatients (UC-
DC) stimulated a significantly weaker proliferation of the
same CFSE-labelled T-cells compared with DC from healthy
controls (control DC; Figure 1(b)).
3.1.2. DC in UC Exhibit an Enhanced Ability to Imprint Skin-
Homing Properties on Effector T-Cells. We have previously
demonstrated T-cells within fresh PBMC expressed either
gut-homing molecule 𝛽7 or skin-homing molecule CLA; the
majority expressed 𝛽7 only. Freshly purified T-cells exhibited
the same homing profile, prior to co-culture with allogeneic
DC [37]. Post-culture, the expression of 𝛽7 on dividing T-
cells (CFSElo) was the default pathway; T-cells stimulated
by both control and UC-DC maintained 𝛽7 expression, as
did unstimulated T-cells. In contrast, CLA expression was
induced on dividing T-cells by both control and UC-DC
so that substantial numbers of T-cells were identified as
double positive for CLA and 𝛽7 following stimulation (due to
inherent high expression of 𝛽7 in all conditions; Figure 2(a)).
However, UC-DC exhibited an enhanced ability to prime
skin-homing T-cells, significantly increasing the proportion
of total CLA+ T-cells (Figure 2(b)) and the proportion of T-
cells expressing skin-homing molecule CCR4 (Figure 2(c))
within the stimulated population.
3.2. Effects of LcS Treatment on Dendritic Cell Function
3.2.1. LcS Restored T-Cell Stimulatory Capacity of Dendritic
Cells in UC. Optimisation experiments on healthy control
DC determined no significant differences between live or
heat-killed (HK) LcS regarding ability to enhance DC acti-
vation/maturation markers CD80 and CD83; both live and
HK LcS significantly enhanced CD80 and CD83 expression
(Figure 3(a)). Therefore HK LcS was used for all further
experiments.
We analysed DC stimulation of T-cells in a 5-day mixed
leucocyte reaction (MLR) following DC conditioning with
complete medium only, or varying concentrations of HK
LcS (1 × 105, 1 × 106, or 1 × 107 CFU/mL). A significant,
dose-dependent increase in DC stimulatory capacity was
observed upon LcS conditioning of both control- and
UC-DC (Figure 3(b)). Following LcS conditioning, UC-DC
levels of stimulation were restored to “normal” levels, similar
to that of control DC (Figure 3(c)).
3.2.2. LcS Conditioned DC to Imprint Skin-Homing Properties
on T-Cells in Healthy Controls but Not UC Patients. LcS
conditioning of DC had differential effects in healthy con-
trols compared with UC, on DC ability to imprint homing
properties on stimulated T-cells. In healthy controls, LcS
conditioning enhanced DC ability to induce a skin-homing
profile on T-cells, significantly increasing the proportion
of stimulated T-cells expressing CLA, in a dose-dependent
fashion (Figures 4(a) and 4(b)). However, in UC, CLA
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Figure 1: RestrictedDC stimulatory capacity inUC. (a) Identification of dividing T-cells followingmixed leucocyte reaction (MLR) according
to flow cytometry forward and side scatter dot plot, and subsequent CD3 and CFSE histograms, respectively. (b) Dose response T-cell
proliferation following MLR. Results are displayed as mean ± SEM (𝑛 = 6). Base-level proliferation is shown as proportion of dividing
T-cells with no DC (0%). After paired two-way ANOVA analysis (corrected with Bonferroni correction for multiple comparisons), the DC
concentrationwas statistically significant in both cases (𝑃 < 0.01) that is, a dose response occurred in both cases. UC-DCwere less stimulatory
than control DC (𝑃 < 0.05 at 1%, 2%, and 3% DC).
expression on T-cells was already enhanced (Figures 2(a) and
2(b)), and LcS conditioning had no further effects on DC
ability to enhance CLA expression on T-cells (Figure 4(b)).
LcS conditioning had no effect on DC ability to induce CCR4
expression in either healthy controls or UC patients (data not
shown).
CLA expression on T-cells was enhanced upon stim-
ulation by both untreated UC-DC and LcS-conditioned
(control) DC. Induction of CLA onT-cells stimulated by LcS-
conditioned DC from controls was in conjunction with gut-
homing marker 𝛽7. However, CLA induction by untreated
UC-DC was on the 𝛽7 negative fraction of T-cells (Fig-
ure 4(c)).Thus, the proportion of CLA+𝛽7− T-cells within the
total CLA+ dividingT-cell pool was significantly greater upon
stimulation with UC-DC, compared to LcS (1 × 107 CFU/mL)
conditioned (control) DC (Figure 4(d)).
3.2.3. LcS Conditioned DC to Induce TGF𝛽 Production by T-
Cells in Healthy Controls but Not UC Patients. LcS condi-
tioning of DC also had differential effects on DC ability to
induce cytokine production by stimulated T-cells, in controls
compared with UC patients. Although there were differences
within individual experiments between the ability of con-
trol DC and UC-DC (both untreated) to induce cytokine
production by T-cells (IL-10, TGF𝛽, IFN𝛾 and IL-17A were
measured), overall there were no significant differences
(Figure 5(a)). However, TGF𝛽 production by T-cells was
significantly increased, in a dose-dependent manner, when
DC were conditioned with LcS in healthy controls, but not
in ulcerative colitis (Figure 5(b)).
4. Discussion
We demonstrate for the first time, that human circulating DC
from UC patients exhibit a restricted stimulatory capacity
for allogeneic T-cells, and these DC induce a specific skin-
homing profile on stimulated T-cells that DC from healthy
controls do not. Our data support studies demonstrating
dysregulatedDC function in IBD [11, 15, 16], and furthermore,
demonstrate systemic immune dysregulation in IBD patients
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Figure 2: UC-DC enhanced expression of skin-homing molecules on stimulated T-cells. (a) CLA/𝛽7 dot plots of dividing T-cells, following
stimulation by 3% control or UC-DC. Numbers over each dot plot represent proportion of dividing T-cells expressing 𝛽7 only, 𝛽7 and CLA,
CLA only or neither 𝛽7 or CLA. (b)Histograms of CLA expression by dividing T-cells, following stimulation by 3% control or UC-DC.On the
right, summary graph of all experiments (𝑛 = 3). (c) Histograms of CCR4 expression by dividing T-cells, following stimulation by 3% control
or UC-DC. On the right, summary graph of all experiments (𝑛 = 3). Paired 𝑡-test was applied, 𝑃-value <0.05 was considered statistically
significant (∗𝑃 < 0.05). All representative histograms/dot plots are from a single experiment representative of 3 independent experiments
performed with similar results. Filled histograms represent positive staining, empty histograms represent background staining.
rather than at mucosal sites only. The occurrence of extra-
intestinalmanifestations (EIM) associatedwith IBD indicates
IBD is indeed a systemic disease, and our data provide an
explanation for the occurrence of EIM affecting the skin
[17]. Conditioning UC-DCwith probiotic strain LcS restored
their stimulatory capacity, reflecting that of control DC.
LcS had differential effects on DC in healthy controls and
UC, on DC ability to imprint specific homing profiles on
stimulated T-cells, and to induce cytokine production by T-
cells. This is the first study, to our knowledge, to investigate
the effects of probiotic bacteria on migratory properties
of immune cells. Our data supports studies demonstrating
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Figure 3: LcS restored “normal”DC stimulatory capacity inUC. (a) Identification of blood-enrichedDC according to flow cytometry forward
and side scatter plot and summary graphs representing mean ± SEM proportions of DC expressing CD40 and CD86 following conditioning
with medium only, live LcS or dead LcS (𝑛 = 3). Separate experiments were carried out conditioning DC with LPS (𝑛 = 3). (b) Dose
response T-cell proliferation following MLR with control- and UC-DC (𝑛 = 6). After paired two-way ANOVA analysis (corrected with
Bonferroni correction for multiple comparisons), the DC concentration was statistically significant in all cases (𝑃 < 0.01). Control- and UC-
DC stimulatory capacity was increased following LcS conditioning at LcS concentrations of 1 × 105 (control: 𝑃 < 0.05 at 2%, UC: 𝑃 < 0.01 at
1%, 𝑃 < 0.05 at 2%, 𝑃 < 0.01 at 3% DC), 1 × 106 (control: 𝑃 < 0.01 at 2% and 3%, UC: 𝑃 < 0.05 at 2%, 𝑃 < 0.01 at 3% DC) and 1 × 107 (control:
𝑃 < 0.01 at 1%, 2%, and 3%, UC: 𝑃 < 0.01 at 2%, and 3%) CFU/mL. (c)There were no significant differences between the stimulatory capacity
of control and LcS-conditioned UC-DC at any LcS concentration.
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Figure 4: Continued.
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Figure 4: LcS conditioning of DC enhanced expression of CLA on stimulated T-cells in healthy controls but not UC. (a) Histograms of CLA
expression by dividing T-cells, following stimulation by 3% DC from healthy control (no LcS) and after conditioning with 1 × 105/1 × 106/1 ×
107 CFU/mL LcS. Example is from one experiment but representative of 3 independent experiments with similar results. (b) Summary graphs
of all experiments, representing proportions of CLA+ T-cells stimulated by 3% control and UC-DC conditioned with increasing doses of LcS
(𝑛 = 3). One way-ANOVA was applied, 𝑃-value <0.05 was considered statistically significant (∗𝑃 < 0.05, ∗∗𝑃 < 0.01). (c) CLA/𝛽7 dot plots
of dividing T-cells, following stimulation by 3% control DC, control DC + 1 × 107 LcS or UC-DC (no LcS). Example is from one experiment
but representative of 3 independent experiments with similar results. Numbers over each dot plots represent proportion of dividing T-cells
expressing 𝛽7 only, 𝛽7 and CLA, CLA only or neither 𝛽7 or CLA. (d) Summary graph of all experiments (𝑛 = 3) representing the proportion
of dividing T-cells (stimulated by 3% DC in all cases) expressing CLA only (i.e., 𝛽7 negative), out of total CLA+ dividing T-cells. Paired 𝑡-test
was applied, 𝑃-value <0.05 was considered statistically significant (∗𝑃 < 0.05, ∗∗𝑃 < 0.01).
multifunctional immunoregulatory activities of LcS, depend-
ing on the responding cell types and the local microenviron-
ment [38].
LcS conditioned control DC, but not UC-DC, to imprint
skin-homing molecule CLA on stimulated T-cells. However,
unlike the skin-homing profile induced on T-cells by UC-
DC, CLA expression induced via LcS conditioning was
in conjunction with gut-homing molecule 𝛽7, suggesting
induction of a multi-homing profile. The differential effects
of LcS on control and UC-DC were further demonstrated
by the induction of TGF𝛽 production by T-cells stimulated
with LcS-conditioned DC in controls but not UC patients.
These data suggest effects of LcS exerted on human DC
are flexible, depending on the responding cell types and
the local cytokine environment. The restoration of UC-
DC stimulatory capacity by LcS suggests LcS may partly
contribute to restoration/maintenance of homeostasis.
LcS may also confer homeostatic properties at intestinal
sites (e.g., via oral administration) which could be beneficial
in IBD; gut DC play a central role in immune home-
ostasis in the gut [39] and exhibit tolerogenic properties
[15]. Alterations occur in gut DC in IBD [15, 16], leading
to loss of tolerance in the gut and dysregulated immune
responses to the colonic microbiota, a major contributing
factor in the onset of IBD [11]. Restoration of homeostatic
properties of gut DC by LcS at intestinal sites may account
for the reported efficacy of LcS in UC [32]. However, the
local microenvironment and responding cell types differ
dramatically in the circulation and the gut for example, gut
DC are conditioned by intestinal epithelial cells and epithelial
cell-derived products to adopt their tolerogenic function
[40–42]. Future studies will determine in vitro effects of LcS
on gut DC and also on epithelial cell conditioning of gut DC.
Although the definition of probiotics involves live
microorganisms (which, when administered in adequate
amounts confers health benefit on the host) [2], our data
demonstrates immunomodulation by heat-killed bacteria;
furthermore, we demonstrated no significant differences
between live and HK LcS regarding their ability to enhance
activation marker expression on blood-enriched DC from
healthy controls. These data support studies demonstrating
immunomodulation by probiotic bacterial products, includ-
ing the ability of probiotic bacterial DNA to induce regulatory
IL-10 production by human peripheral blood mononuclear
cells [43] and dendritic cells [44], and the ability of soni-
cated probiotic bacteria to induce marked anti-inflammatory
effects on blood and intestinal DC. Furthermore, our recent
studies have demonstrated an immunomodulatory peptide
secreted by Lactobacillus plantarum, mediates some of the
molecular dialogue between intestinal bacteria and DC,
inducing immunoregulatory effects in both blood and intesti-
nal DC in vitro [45].
IBD is associated with a variety of EIM, with up to a third
of patients developing cutaneous manifestations including
erythema nodosum (EN) and pyoderma gangrenosum (PG)
[17]. The causes of EIM of IBD are poorly understood, but it
has been suggested that compartmentalisation of inflamma-
tory processes to different organs (e.g., intestine, skin, liver)
may be linked to homing and trafficking of immune cells. For
example, CCL25, the ligand for gut-homing receptor CCR9,
is expressed on epithelium in both the liver and the small
intestine [18]. Dysregulation of lymphocyte trafficking plays
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Figure 5: Intracellular cytokine production by stimulated T-cells. (a) Summary graphs of all experiments representing proportions of T-
cells stimulated by 3% control and UC-DC producing TGF𝛽, IL-10, IFN𝛾 and IL-17 (𝑛 = 3). Paired 𝑡-tests were applied, 𝑃-value <0.05 was
considered statistically significant. (b) Histograms of TGF𝛽 expression by dividing T-cells, following stimulation by 3% control (no LcS) DC
or control DC + 1 × 105/1 × 106 or 1 × 107 CFU/mL LcS. Example is from one experiment but representative of 3 independent experiments with
similar results. Below, summary graphs of all experiments (𝑛 = 3) representing the proportion of dividing T-cells (stimulated by 3% DC in
all cases) producing TGF𝛽. DC were from healthy controls (left graph) or UC patients (right graph). One way-ANOVA was applied, 𝑃-value
<0.05 was considered statistically significant (∗𝑃 < 0.05).
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a key role in IBD pathogenesis [19–22, 46] and IBD thera-
peutics have previously demonstrated efficacy by abrogating
trafficking of effector cells to intestinal sites [47–51]. However,
we demonstrate in this study that skin-homing markers CLA
and CCR4 are aberrantly expressed on 𝛽7− T-cells stimulated
by UC-DC, providing an explanation for the occurrence
of EIM affecting the skin, and supporting previous studies
demonstrating conditioning DC with supernatants from
culture of colonic biopsies from UC patients enables them
to imprint a skin-homing phenotype on stimulated T-cells
[52]. Blocking trafficking of effector cells to cutaneous sites in
patients with EIM of IBD may also be of therapeutic benefit.
Although there were no significant effects of LcS on DC
ability to induce T-cell cytokine production in UC overall,
effects of LcS were variable between individual experiments,
depending on whether production of particular cytokines
were increased or decreased compared to T-cells stimulated
by control DC (data not shown). These data also suggest
restoration of a “normal” phenotype and support amultifunc-
tional immunoregulatory role for LcS, returning dysregulated
immune functions to the original normal state when the
host becomes either immunocompromised or excessively
activated [38]. Indeed, LcS can have either pro- or anti-
inflammatory effects in human intervention studies [32, 53,
54] and in vitro studies [55–57] depending on the context.
In summary, our data demonstrate systemic alterations in
immune cells in UC, specifically a dysregulated DC function.
Our data provides an explanation for the occurrence of EIM
of the skin in UC patients, and suggests that the probiotic
strain LcS has multifunctional immunoregulatory activities
on DC, depending on the disease state and the inflamma-
tory environment. Our data supports studies demonstrating
probiotic bacterial products, rather than live bacteria are
capable of inducing immunoregulatory effects. The reported
therapeutic effects of LcS and other probiotic Lactobacilli
strains in UC [32, 58] may be partly due to promotion of
homeostasis, restoring the dysregulated functions of immune
cells.
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